TAGLN2 and cholangiocarcinoma: TAGLN2 suppression inhibited cancer cell proliferation and reduced resistance to conventional anti-cancer drugs; therefore, TAGLN2 can be applied to most patients with cholangiocarcinoma, suggesting that it is a novel therapeutic target with fewer off-target effects.